ProKidney Corp. (PROK) shares surged 496.87 percent to $3.62 on Tuesday after the company announced positive topline results from its Phase 2 REGEN-007 trial evaluating rilparencel, a potential treatment for chronic kidney disease in patients with diabetes.
Shares opened at $1.27 and traded between $1.02 and $4.45 on the day, with volume spiking to 292.2 million shares, far above the 1.1 million average on the Nasdaq. The stock now trades near its 52-week high of $4.45, after closing at just $0.61 the previous session.
The therapy, which has FDA RMAT designation, showed statistically significant improvements in kidney function, bolstering confidence in its ongoing Phase 3 PROACT 1 trial. ProKidney plans to submit the full REGEN-007 data for presentation at the 2025 ASN Kidney Week and is preparing for an upcoming FDA Type B meeting regarding accelerated approval pathways.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.